Traditional therapies against cancer, chemo-and radiotherapy, have multiple limitations that
lead to treatment failure and cancer recurrence. These limitations are related to systemic …

Cancer poses a serious health problem in society and is increasingly surpassing
cardiovascular disease as the leading cause of mortality in the United States. Current …

Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label,
multicenter study (ClinicalTrials. gov, NCT01546038) evaluated the efficacy of glasdegib …

Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML)
undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging …

The past decade has seen significant advances in our understanding of Hedgehog (HH)
signaling pathway in various biological events. HH signaling pathway exerts its biological …

Background The hedgehog signaling pathway is normally tightly regulated. Mutations in
hedgehog pathway components may lead to abnormal activation. Aberrantly activated …

Acute myeloid leukemia (AML) is the most commonly diagnosed leukemia in adults (25%)
and comprises 15–20% in children. It is a genetically heterogeneous aggressive disease …

Breast cancer (BC) is the leading cause of cancer-related mortality in women, only followed
by lung cancer. Given the importance of BC in public health, it is essential to identify …

Abstract Targeting Hedgehog (Hh) pathway components, such as Smoothened (SMO), is a
develo** strategy for the treatment of acute myeloid leukemia (AML) and for overcoming …

Aberrant activation of the Hedgehog signaling pathway has been implicated in the
maintenance of leukemia stem cell populations in several model systems. PF‐04449913 (PF …